News
Cumulative inflammatory burden predicts cancer risk in ulcerative colitis
Second study validates cumulative microscopic inflammation score as independent predictor of colorectal neoplasia.
News
Telerheumatology will thrive post pandemic
Physician-to-physician teleconsults and remote patient monitoring are predicted to be growth areas.
News
Point-Counterpoint: The future of rheumatology is sub-subspecialization
The rheumatology workforce shortage is here and growing.
News
Checkpoint inhibitor–induced rheumatic complications often arise late
Rheumatologic adverse events associated with immune checkpoint inhibitors can happen later in the course of treatment but also can continue after...
News
Evidence grows for food as RA treatment
An enhanced anti-inflammatory diet shows promise for symptom reduction.
News
To improve psoriatic arthritis outcomes, address common comorbidities
Depression and obesity are associated with poor treatment response in PsA.
News
Novel lupus therapies take center stage
Speakers at the 2021 Rheumatology Winter Clinical Symposium spotlighted new drug approvals and new mechanisms of action in SLE, as well as...
News
Recent psoriasis pathophysiology insights carry treatment implications
“The primary problem in psoriasis is not so much the inflammatory activity, but the ability to turn off the activity.”
News
RA experts highlight key developments over the past year
Highlights include lymphoma risk reduction with biologics, low-dose corticosteroid risk, stratifying VTE risk, treat-to-target strategies and...
News
Rise of JAK inhibitors highlights axial spondyloarthritis year in review
Panelists at the 2021 Rheumatology Winter Clinical Symposium discussed the impact JAK inhibitors will have on the management of patients with...
News
Romosozumab may not increase cardiovascular risk after all
Could a cardioprotective effect of bisphosphonates in a pivotal clinical trial of romosozumab explain why the biologic was given a black-box...
News
Consider home subcutaneous immune globulin for refractory dermatomyositis
Patients prefer home subQ over IVIg, citing greater feeling of autonomy.
News
Molecular insights suggest novel therapies for hidradenitis suppurativa
Many key molecular pathways involved in HS pathogenesis can be targeted by commercially available agents having other indications.
News
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2b
Sonelokinab, which inhibits interleukin-17A/F, provided exceptionally rapid clinical improvement.
News
Neoadjuvant immunotherapy shows promise in stage III melanoma
There is both preclinical and clinical evidence that neoadjuvant therapy may offer a survival advantage over adjuvant therapy.